Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS): Education for Healthcare Providers
December 21, 2018
December 21, 2019
Scroll to the Bottom of this Information to Begin this Course
Jointly provided by Global Education Group and Rockpointe.
This educational activity is supported by an independent educational grant from the Extended-Release/Long-Acting Opioid Analgesic REMS Program Companies.
Please see http://ce.er-laopioidrems.com/IwgCEUI/rems/pdf/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Extended-Release/Long-Acting Opioid Analgesics REMS education requirements issued by the US Food & Drug Administration.
- Physicians — maximum of 3.0 AMA PRA Category 1 Credit(s)™
- Nurses — maximum of 3.0 contact hours
- Pharmacists — maximum of 3.0 contact hours (0.3 CEUs)
- Nurse Practitioners — maximum of 3.0 contact hours which includes 0.5 hours of pharmacology
All other healthcare professionals completing this course will be issued a statement of participation.
The educational design of this activity addresses the needs of primary care physicians and other healthcare professionals involved in the treatment of patients with chronic pain.
Pain is a significant public health problem, affecting more than 100 million adults in the US and causing significant reductions in patients’ quality of life. The use of narcotic medications for pain management has increased dramatically in the US over the past two decades. However, pain patients are often undertreated due to a variety of physician- and patient-related concerns and barriers.
In addition, despite the pain-relieving properties of opioid medications, the potential for abuse remains a concern. In response to this apprehension about opioid misuse, overdose, abuse, and addiction, the Food and Drug Administration (FDA) developed the Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits outweigh the risks for long-acting and extended-release opioid analgesics.
The activity, Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS): Education for Healthcare Providers, incorporates the REMS blueprint into education that is designed to induce changes in knowledge, competence, and performance that will translate into improved quality of patient care and reduced pain for patients.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Describe components of an effective treatment plan, such as treatment goals, patient interactions, and collaboration with the healthcare team
- Compare the individualized benefits and risks to initiating non-medication therapies before considering long-term medications
- Identify patients who are candidates for treatment with nonopioid pharmacologic analgesics
- Justify a rational decision to initiate long-term opioid analgesics, including ER/LA opioids, with consideration to providing in-home naloxone
- Categorize risk factors and vulnerabilities associated with addiction to opioid analgesics
Lynn R. Webster, MD
Vice President of Scientific Affairs
PRA Health Services
Salt Lake City, UT
Bill McCarberg, MD
Adjunct Assistant Clinical Professor
University of California
San Diego, CA
Jeffrey Fudin, PharmD, DAIPM, FCCP, FASHP, FFSMB
Chief Executive Officer
Clinical Pharmacy Specialist
Director, PGY-2 Pharmacy Pain Residency Program
Stratton Veterans Administration Medical Center
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Rockpointe Corporation. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring materials for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 3.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Continuing Education
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Global Education Group designates this continuing education activity for 3.0 contact hours (0.3 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-18-425-H01-P).
This is a knowledge-based activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through joint providership of Global Education Group and Rockpointe. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 1561024. This activity is approved for 3 contact hour(s) which includes 0.5 hours of pharmacology.
Activity ID #2538E
This activity was planned in accordance with AANP CE Standards and Policies.
Physician Assistant Continuing Education
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 3.0 hours of Category 1 credit for completing this program.
Disclosures of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lynn R. Webster, MD (Chair)
- Consultant/Independent Contractor: Alcobra, Daiichi Sankyo, Depomed, Egalet, Indivior, Inspiron, Insys, Kempham, Pain Therapeutics, Pfizer, Shionogi, Teva
Jeffrey Fudin, PharmD, DAIPM, FCCP, FASHP, FFSMB
- Speakers’ Bureau: AstraZeneca
- Advisory Board: Daiichi Sankyo, Eaglet, Quest Labs
- Consultant: Eaglet
- Owner: Remitigate, LLC
Bill McCarberg, MD
- Consultant/Independent Contractor: Charleston Labs, Collegium, Daiichi Sankyo, Ferring, Pernix, Pfizer
- Speakers’ Bureau: Collegium
- Stock Shareholder: Biospecifics Technologies, Callegium, Galena, Johnson & Johnson
Non-faculty Content Contributors
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Kristen Delisi, NP; Andrea Funk; Kathy Merlo; Ashley Marostica, RN, MSN; Lindsay Borvansky; Liddy Knight; Blair St. Amand: Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Rockpointe Corporation do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings
Instructions for Participation and Credit
There is no fee for this educational activity. In order to receive credit, you must watch the webcast, pass the posttest with a score of 70% or greater, and complete the evaluation. You will have 5 opportunities to take and pass the posttest.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com.
Hardware and Software Requirements
This site is best viewed with an HTML5 compatible browser, this list includes the versions of Mircrosoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This course is not intended to advocate for the use of Extended-Release/Long-Acting (ER/LA) Opioids, but to ensure the proper education about safe prescribing practices should a medical provider determine that ER/LA Opioids are the best course of treatment.